Pancreatic Ductal Adenocarcinoma Clinical Trials in Boston, Massachusetts

13 studies are recruiting for pancreatic ductal adenocarcinoma in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

   Some people with pancreatic ductal cancer (PDAC) have a protein called Claudin 18.2 (CLDN18.2) in their tumor. ASP2138 is thought to work by binding to CLDN18.2 and a protein on a type of immune cell called a T-cell. The T-cell "tells" the immune system to attack the tumor. This study is for people…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   3 in total

   Run by

   Astellas Pharma Global Development, Inc.

   See if you can join NCT07024615 on ClinicalTrials.gov

2. Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

   This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may hel…

   Stage

   Phase 1

   Ages

   1 to 30

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Locations

   21 in total

   Run by

   Children's Oncology Group

   See if you can join NCT04851119 on ClinicalTrials.gov

3. Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

   Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Boston, Massachusetts

   Locations

   18 in total

   Run by

   AstraZeneca

   See if you can join NCT06218914 on ClinicalTrials.gov

4. MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

   The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Locations

   52 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06586515 on ClinicalTrials.gov

5. Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

   This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   55 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT06128551 on ClinicalTrials.gov

6. Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

   The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + 5…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   32 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT06445062 on ClinicalTrials.gov

7. Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

   The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-NNS309 and the safety, dosimetry and imaging properties of [68Ga]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-…

   Stage

   Phase 1

   Ages

   18 to 100

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   29 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06562192 on ClinicalTrials.gov

8. Pancreatic Cancer Early Detection Consortium

   The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying…

   Stage

   Not phased

   Ages

   18 to 90

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   60 in total

   Run by

   Arbor Research Collaborative for Health

   See if you can join NCT04970056 on ClinicalTrials.gov

9. A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

   This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Beth Israel Deaconess Medical Center, Boston, Massachusetts

   Locations

   48 in total

   Run by

   Seagen, a wholly owned subsidiary of Pfizer

   See if you can join NCT06131840 on ClinicalTrials.gov

10. Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

    This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig (PT886). Patients with the following tumor types will be eligible for s…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts

    Locations

    11 in total

    Run by

    Phanes Therapeutics

    See if you can join NCT05482893 on ClinicalTrials.gov

11. Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals

    The purpose of this research is to see if adding blood-based tests and symptom review to standard-of-care pancreatic cancer screening procedures can identify cancer early among individuals with increased risk.

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Dana Farber Cancer Institute, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT06122896 on ClinicalTrials.gov

12. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    14 in total

    Run by

    Verastem, Inc.

    See if you can join NCT07020221 on ClinicalTrials.gov

13. SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

    The clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on metastatic pancreatic cancer and metastatic breast cancer. The investigational treatment will involve 2 cycles of a combination of intravenous melphalan, BCNU, vitamin B12b, and vitam…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    General Oncology, Inc.

    See if you can join NCT04150042 on ClinicalTrials.gov